Abstract
BackgroundTherapeutically targeting tumor myeloid cells has emerged as a novel and complementary strategy to existing cancer immunotherapy approaches. The interaction of tumor expressed CD47 with SIRP alpha (signal regulatory protein-alphaa,...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have